Expanding sales

LEO Pharma is a research based, international, specialty pharma company focused on critical care and dermatology. We have recently launched a growth strategy with the goal of creating a global sales and marketing platform within specialist diseases. Business development will help to add new products to this platform.

LEO net sales, 2008
In 2008, our revenue was MEUR 766. Break down will change with recent transaction to re-acquire US rights to our US psoriasis portfolio.
 

Product sales in 2008
Our focus is on both dermatology and critical care. Our two current strategic products are Daivobet®/taclonex® within psoriasis and Innohep® within coagulation. Futher to this, we are expecting to add a third, new strategic, therapeutic focus area to our development pipeline in the coming years.